Genetic Research in Schizophrenia

This study has been completed.

First Received: April 14, 2005 Last Updated: March 2, 2009 History of Changes

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00108303

Purpose

Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause childhood and adult onset schizophrenia.

Condition
Schizophrenia

Study Type:	Observational
Official Title:	Genetic Research in Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:

January 2004

Groups/Cohorts
1

Detailed Description:

It is known from genetic linkage and gene expression studies that the alpha 7 nicotinic receptor gene is abnormally expressed in people with schizophrenia. The immediate objectives of this proposal support the long-term objectives of a comprehensive description of the pathophysiology of schizophrenia and new drug treatments by carefully defining the physiological genotype-phenotype relationship for a single candidate gene.

Subjects and family members with a mental illness or who appear to have a mental illness will be asked to undergo an interview, perform some mental tests and have a blood, urine, and saliva sample taken one time.

Eligibility

Ages Eligible for Study:	5 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Individuals thought to have schizophrenia or schizoaffective disorder, be the parent of such an individual, or be in the matched control group of unrelated individuals not thought to have schizophrenia or schizoaffective disorder

Exclusion Criteria:

Unable to give informed consent;
Psychotic disorder judged to be secondary to substance abuse, psychotic disorder that appears to be secondary to a known medical or neurological disorder, or severe mental retardation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108303

Locations

United States, Colorado
VA Eastern Colorado Health Care System, Denver
Denver, Colorado, United States, 80220

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Principal Investigator:

Robert Freedman, MD

VA Eastern Colorado Health Care System, Denver

More Information

No publications provided

Responsible Party:	Department of Veterans Affairs ( Freedman, Robert - Principal Investigator )
Study ID Numbers:	ADRD-007-03S
Study First Received:	April 14, 2005
Last Updated:	March 2, 2009
ClinicalTrials.gov Identifier:	NCT00108303 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

schizophrenia

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on September 03, 2009